PHARVARIS NV (PHVS:NASDAQ)
$27.74 -1.9 (-6.4103%)
Analysed PHARVARIS NV (PHVS:NASDAQ) News Sources
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
08-09-2026
yahoo.com
Pharvaris Shares Surge 27% After Deucrictibant Phase 3 Trial Meets Primary Endpoint
08-09-2026
advfn.com
Biotech Stocks, With 'Blowout' And 'Bull Case' Results, Rocket To Record Highs
08-09-2026
yahoo.com
Pharvaris charts approval course for swelling disorder drug on Phase III win
09-09-2026
clinicaltrialsarena.com
Pharvaris Could Gain Hereditary Angioedema Market Share on Deucrictibant XR Data, RBC Says
09-09-2026
yahoo.com
Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win?
10-09-2026
yahoo.com
What Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now?
19-09-2026
yahoo.com
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
05-10-2026
yahoo.com
Could Real-World HAE Oral Preference Data Be a Pivotal Signal for Pharvaris' (PHVS) Strategy?
08-10-2026
yahoo.com
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
08-10-2026
yahoo.com
What is the current price of PHARVARIS NV (PHVS:NASDAQ)?
The current price of PHARVARIS NV (PHVS:NASDAQ) is $27.74.
PHARVARIS NV (PHVS:NASDAQ) absolute price change since previous trading day?
The absolute price change of PHARVARIS NV (PHVS:NASDAQ) since the previous trading day is $-1.9.
PHARVARIS NV (PHVS:NASDAQ) percentage price change since previous trading day?
The percentage price change of PHARVARIS NV (PHVS:NASDAQ) since the previous trading day is -6.4103%.
What is the most recent average sentiment score for PHARVARIS NV (PHVS:NASDAQ)?
The most recent average sentiment score for PHARVARIS NV (PHVS:NASDAQ) is 47 out of 100.
What is the most recent average sentiment for PHARVARIS NV (PHVS:NASDAQ)?
The most recent sentiment for PHARVARIS NV (PHVS:NASDAQ) is .
SEC-8K** Filing Available For PHARVARIS NV (PHVS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.